Abstract:To determine the role of hepatitis C virus (HCV) genotype 1 b genetic variation in the open reading frame for treatment outcomes of the pegylated-interferon/ribavirin (peg-IFN/RBV) combination therapy by examining patients from Henan Province with chronic hepatitis C (CHC).Thirty-seven treatment naive patients infected with HCV genotype 1b were included in the study. Prior to initiation of a 48-week course of peg-IFN/RBV therapy, peripheral blood was drawn for sequencing of the viral ORF 5'-half. Patients were assessed at the end of the 48 weeks of treatment and at a 6-month follow-up appointment. The patient data was stratified according to the status of sustained viral response (SVR) group and non-response (NR) and statistical analysis was performed to determine the correlation between detected genetic variations and treatment response status.Genetic variability in the ORF 5'-half was significantly higher among the individuals in the SVR group than among those of the NR group. Significant differences were found in the gene regions encoding p7, NS2 and NS3. For p7, the NR group had actual and expected frequencies of special mutation of 9.0 and 17.4 and total mutation of 77.0 and 68.6, while the SVR group had actual and expected frequencies of special mutation of 42.0 and 33.6 and total mutation of 124.0 and 132.4 (x2 =7.725, P =0.05). For NS2, the NR group had actual and expected frequencies of special mutation of 36.0 and 54.3 and total mutation of 270.0 and 251.7, while the SVR group had actual and expected frequencies of special mutation of 106.0 and 87.7 and total mutation of 388.0 and 406.3 (x2 = 12.16, P less than 0.01). For NS3, the NR group had actual and expected frequencies of special mutation of 49.0 and 53.4 and total mutation of 241.0 and 236.6, while the SVR group had actual and expected frequencies of special mutation of 81.0 and 76.6 and total mutation of 335.0 and 339.4 (x2 =6.745, P =0.043). The inter-patient genetic variations in the NS3 gene were concentrated in the protease domain. Furthermore, there was a strong correlation between HCV diversity in p7 and treatment outcome.The genetic data reported here provides strong support for the role of NS2, NS3 and p7 in antagonizing the peg-IFN/RBV response during the treatment of HCV infections. We conclude that higher inter-patient viral genetic diversity correlates with successful treatment and may modulate the efficacy of antiviral therapy in CHC patients of Henan.

Association of Single Nucleotide Polymorphisms in Interferon Signaling Pathway Genes and Interferon-Stimulated Genes with the Response to Interferon Therapy for Chronic Hepatitis C

A Functional SNP of Interferon-Γ Gene is Important for Interferon-Α-induced and Spontaneous Recovery from Hepatitis C Virus Infection

Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.

ZNF350 gene polymorphisms promote the response to Peg-IFNα therapy through JAK-STAT signaling pathway in patients with chronic hepatitis B

Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China

Genetic Variation in NOS2A is Associated with a Sustained Virological Response to Peginterferon Plus Ribavirin Therapy for Chronic Hepatitis C in Taiwanese Chinese.

Polymorphisms of Interferon-Inducible Genes OAS Associated with Interferon-Α Treatment Response in Chronic HBV Infection

The Impact of Polymorphisms in STAT6 on Treatment Outcome in HCV Infected Taiwanese Chinese

An intronic genetic variant of ZHX2 predicts response to pegylated interferon α therapy in HBeAg-positive chronic hepatitis B patients

Association of IFNL3/IFNL4 Polymorphisms with Efficacy of Highly Active Antiretroviral Therapy in Patients with HIV-1 Infection

Association of Genetic Variations in GNB1 with Response to Peginterferon Plus Ribavirin Therapy for Chronic Hepatitis C in a Chinese Population in Taiwan

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study

What are the limits of efficacy for immunotherapy against hepatocellular carcinoma and its clinical availability

Evaluation of Susceptibility Locus for Response to Interferon-Α Based Therapy in Chronic Hepatitis B Patients in Chinese

Genetic Variation in STAT4 Predicts Response to Interferon‐α Therapy for Hepatitis B E Antigen‐positive Chronic Hepatitis B

Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C

Mir-196A-2 Gene Polymorphism and the Antiviral Therapy of Chronic Hepatitis C

Association of Interferon-Γ-induced Protein-10 Serum Levels with Virological Responses to PEG-interferon-based Therapy in Hepatitis C Virus Genotype 1 or 2 Chronically Infected Chinese Patients.

Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection

IFIT1 Polymorphisms Predict Interferon-Α Treatment Efficiency for Hepatitis B Virus Infection.

Association of MRC-1 and IL-28B with the Treatment Outcome of Hepatitis C: a Case Control Study.